This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cumberland Pharmaceuticals Inc.
Drug Names(s): acetylcysteine
Description: The most accepted explanation for the protective actions of acetylcysteine is that it serves as a source of L-cysteine for glutathione (GSH) synthesis. Hence, GSH can facilitate the detoxification of NAPQI, a toxic metabolite of acetaminophen, before it can initiate hepatic injury. A more recent proposal is that this cysteine analog acts as a scavenger of ROS and OONO- and that it supports mitochondrial energy metabolism.
Cumberland and Harbin Gloria
In February 2012, Cumberland entered into an exclusive agreement with Harbin Gloria Pharmaceuticals for the commercialization of Acetadote and Caldolor Injection. The agreement will provide Harbin Gloria exclusive rights to register and commercialize both drugs in China. Under the terms of the agreement, Harbin Gloria is responsible for seeking regulatory approval for the two injectable products in China, and would handle ongoing regulatory reporting, product marketing, distribution and sales in the territory following approval. Cumberland maintains responsibility for the intellectual property, product formulation, development and other supporting activities. In exchange for the license to the product, Cumberland will receive upfront and milestone licensing payments, as well as royalties on future sales of both drugs.
Partners: Harbin Gloria Pharmaceuticals Co., Ltd.
Additional information available to subscribers only: